Insider Buying: Braveheart Bio (NASDAQ:BRVE) Director Buys $34,920,000.00 in Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director Erez Chimovits bought 1,940,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were purchased at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the transaction, the director owned 11,901,826 shares in the company, valued at $214,232,868. This represents a 19.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Braveheart Bio Trading Down 0.7%

Shares of BRVE stock opened at $25.97 on Friday. Braveheart Bio, Inc. has a twelve month low of $24.61 and a twelve month high of $32.00.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.